Drug intelligence / Profile preview

MS2101

Development stage: Unknown
Lead developer: Medinno
Modality: Stem Cell Therapies → Cell Therapies

Overview

MS2101 is an investigational cell therapy composed of adult human neural stem cells (ahNSC), developed by Medinno for the treatment of stroke. The therapy is designed to promote the repair and regeneration of brain tissue following a stroke event, leveraging the inherent neurogenic and neuroprotective properties of neural stem cells. By transplanting these cells into the affected area, the treatment aims to restore lost neurological functions and improve clinical outcomes for patients. MS2101 is currently in Phase 1 clinical development.

Other names: Adult Human Neural Stem CellsahNSC

Beyond the preview

Go deeper on MS2101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MS2101.

Explore the full profile